5-fluorouracil (5-FU) based chemotherapy is the most common first line regimen used in gastric and gastroesophageal junction cancer, but development of severe toxicity is a main concern in the treatment. The present study is aimed to evaluate a novel pre-treatment assay, known as the 5-FU degradation rate (5-FUDR), as a predictive factor for 5-FU toxicity.

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer / Borro, Marina; Botticelli, Andrea; Mazzuca, Federica; Onesti, Elisa Concetta; Gentile, Giovanna; Romiti, Adriana; Cerbelli, Bruna; Mazzotti, Eva; Marchetti, Luca; Lionetto, Luana; Simmaco, Maurizio; Marchetti, Paolo. - STAMPA. - 8:(2016), pp. 14050-14057. [10.18632/oncotarget.12571]

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer

BORRO, Marina;BOTTICELLI, ANDREA;MAZZUCA, FEDERICA;GENTILE, Giovanna;ROMITI, ADRIANA;CERBELLI, BRUNA;Mazzotti, Eva;SIMMACO, Maurizio;MARCHETTI, PAOLO
2016

Abstract

5-fluorouracil (5-FU) based chemotherapy is the most common first line regimen used in gastric and gastroesophageal junction cancer, but development of severe toxicity is a main concern in the treatment. The present study is aimed to evaluate a novel pre-treatment assay, known as the 5-FU degradation rate (5-FUDR), as a predictive factor for 5-FU toxicity.
2016
5-FU degradation rate; 5-FU toxicity; DPYD; gastro-esophageal cancer; phenotypic test
01 Pubblicazione su rivista::01a Articolo in rivista
Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer / Borro, Marina; Botticelli, Andrea; Mazzuca, Federica; Onesti, Elisa Concetta; Gentile, Giovanna; Romiti, Adriana; Cerbelli, Bruna; Mazzotti, Eva; Marchetti, Luca; Lionetto, Luana; Simmaco, Maurizio; Marchetti, Paolo. - STAMPA. - 8:(2016), pp. 14050-14057. [10.18632/oncotarget.12571]
File allegati a questo prodotto
File Dimensione Formato  
in gastroesophageal 5fu 2016.pdf

solo utenti autorizzati

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 910.28 kB
Formato Adobe PDF
910.28 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/896658
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 5
social impact